Clovis Oncology (NASDAQ:CLVS)

CAPS Rating: 2 out of 5

Caps

How do you think CLVS will perform against the market?

Add Stock to CAPS Watchlist

All Players

60 Outperform
18 Underperform
 

All-Star Players

17 Outperform
6 Underperform
 

Wall Street

6 Outperform
2 Underperform
 

Top CLVS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.85)
Submitted February 16, 2016

Clovis isn't exactly flying under the radar ahead of the rociletinib Ad Comm on April 12. There's lots of commentary on the drug's prospects for approval, most of it negative. Of course, the shocking aspect of the whole situation was the blase way in… More

TerryHogan (99.97)
Submitted October 10, 2018

The financials on this one are fishier than a murder mystery dinner theater in Newfoundland. You can expect SG&A to go up in line with revenue a bit, but why does R&D increase with every revenue increase to wipe out all profits? I'm not saying… More

CLVS VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about CLVS.

Recs

0
Member Avatar LazyHarlequin (86.03) Submitted: 10/31/2018 10:49:30 AM : Underperform Start Price: $12.37 CLVS Score: -72.00

On 10/31/18 down $4.47 to $12.12. Options available.

Recs

1
Member Avatar TerryHogan (99.97) Submitted: 10/10/2018 1:15:18 AM : Underperform Start Price: $29.06 CLVS Score: +19.37

The financials on this one are fishier than a murder mystery dinner theater in Newfoundland. You can expect SG&A to go up in line with revenue a bit, but why does R&D increase with every revenue increase to wipe out all profits? I'm not saying they're cooking the books, but at the very least it looks like they store their Harry Potter collection in the oven.

Recs

0
Member Avatar Bigsef77 (67.88) Submitted: 10/2/2018 10:16:34 AM : Outperform Start Price: $12.96 CLVS Score: -45.17

Clovis Oncology stock rises 10% premarket after 'breakthrough' designation from FDA

,MarketWatch•October 2, 2018
Clovis Oncology Inc. shares rose nearly 10% in Tuesday premarket trade after the company's cancer drug Rubraca got a "breakthrough therapy" designation from the Food and Drug Administration. The designation could expedite the development and review of Rubraca by the FDA for BRCA1/2-mutated metastatic castration-resistant prostate cancer. The company plans to present the phase 2 trial data that "served as the basis of our [breakthrough therapy designation] at the [European Society for Medical Oncology] conference later this month," Clovis Chief Executive Patrick Mahaffy said. Metastatic castration-resistant prostate cancer refers to a type of cancer that has spread beyond the prostate and continues to spread in spite of treatments intended to manage the disease. Called mCRPC, it is incurable and usually associated with poor prognosis, according to Clovis. Clovis is also testing Rubraca in a number of other types of cancer, including in combination with a Bristol-Myers Squibb immunotherapy; the drug has not been approved in the U.S. Clovis shares have dropped 35.5% over the last three months, compared with a 7.3% rise in the S&P 500 and a 9.6% rise in the Dow Jones Industrial Average .

Leaderboard

Find the members with the highest scoring picks in CLVS.

Score Leader

anchak

anchak (99.90) Score: +387.02

The Score Leader is the player with the highest score across all their picks in CLVS.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
kurzzz 71.54 6/25/2013 Underperform 5Y $65.00 -68.06% +64.36% +132.42 0 Comment
ExpressRocks 90.09 6/25/2013 Underperform 5Y $63.88 -67.50% +64.30% +131.80 0 Comment
bluebare 32.11 6/14/2013 Underperform 5Y $69.38 -70.08% +59.81% +129.89 0 Comment
kevian 91.69 6/3/2013 Underperform 1Y $71.74 -71.06% +58.70% +129.76 0 Comment
goldminingXpert 28.84 5/13/2013 Underperform NS $37.75 -45.01% +59.07% +104.08 0 Comment
IBDContrarian 66.41 4/8/2013 Underperform 5Y $29.05 -28.54% +67.75% +96.29 1 Comment
GuruCashFlow 48.46 10/6/2014 Underperform 5Y $48.79 -57.45% +31.99% +89.44 0 Comment
GuruExp 69.29 10/7/2014 Underperform 5Y $47.02 -55.85% +33.38% +89.23 0 Comment
navychop2 40.82 6/12/2014 Underperform 1Y $43.34 -52.10% +33.81% +85.91 2 Comments
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. evergreen5555 74.43 4/18/2017 Underperform 5Y $56.31 -63.13% +11.28% +74.42 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackRBCCapMkts 84.93 2/22/2018 Outperform NS $58.88 -64.74% -3.92% -60.82 0 Comment
TrackCreditSuiss 88.72 9/21/2016 Outperform NS $37.28 -44.31% +21.58% -65.89 0 Comment
TrackGoldmanSach 74.44 4/13/2015 Outperform NS $84.50 +4.28% +1.37% +2.91 7/20/2015 @ $88.12 0 Comment
TrackStifel 91.89 6/5/2014 Outperform NS $39.65 -47.64% +34.67% -82.31 0 Comment
TrackJimCramer 85.30 10/1/2013 Outperform 3W $62.04 -66.54% +53.81% -120.35 0 Comment
TrackCitigroup 92.52 9/20/2013 Outperform NS $78.17 -48.43% +11.69% -60.13 6/3/2014 @ $40.31 0 Comment
trackmizuho < 20 6/25/2013 Outperform NS $65.00 -68.06% +64.36% -132.42 0 Comment
TrackJimCramer 85.30 6/14/2013 Underperform 3W $67.23 -7.72% +3.77% +11.49 10/1/2013 @ $62.04 0 Comment
TrackPiperJaff 85.25 6/6/2013 Outperform NS $74.00 -71.95% +61.58% -133.53 0 Comment
TrackUltraLong < 20 3/21/2013 Underperform NS $27.54 -24.62% +68.31% +92.92 1 Comment
TrackPoisedTo < 20 12/6/2012 Underperform 5Y $15.60 +33.08% +84.25% +51.17 0 Comment

Advertisement